Form 8-K

8-K — InMed Pharmaceuticals Inc.

Accession: 0001213900-26-039943

Filed: 2026-04-03

Period: 2026-04-03

CIK: 0001728328

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — ea0284989-8k_inmed.htm (Primary)

EX-5.1 — OPINION OF NORTON ROSE FULBRIGHT CANADA LLP REGARDING LEGALITY OF SECURITIES BEING REGISTERED (ea028498901ex5-1.htm)

GRAPHIC (ea028498901_ex5-1img1.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — CURRENT REPORT

8-K (Primary)

Filename: ea0284989-8k_inmed.htm · Sequence: 1

false

0001728328

2026-04-03

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

April 3, 2026

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

British Columbia

001-39685

98-1428279

(State or Other Jurisdiction

of Incorporation)

(Commission File Number)

(IRS Employer

Identification No.)

InMed Pharmaceuticals Inc.

Suite 1445 - 885 W. Georgia Street,

Vancouver, B.C.

Canada

V6C 3E8

(Address of Principal Executive Offices)

(Zip Code)

Company’s telephone number, including

area code: (604) 669-7207

Not applicable

(Former Name or Former Address, if Changed Since

Last Report)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see

General Instruction A.2. below):

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange

on which registered

Common Shares, no par value

INM

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the

Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check

mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting

standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

As previously reported, InMed Pharmaceuticals

Inc. (the “Company”) entered into an At The Market Offering Agreement dated April 7, 2022, as amended by that certain amendment

dated June 27, 2024 (the “Sales Agreement”), with H.C. Wainwright & Co., LLC. On April 3, 2026, the Company filed a prospectus

supplement and related prospectus related to the sale of its common shares in accordance with the terms of the Sales Agreement with the

Securities and Exchange Commission (the “Commission”) pursuant to the Company’s shelf registration statement on Form

S-3 (File No. 333-294503) filed on March 20, 2026 and declared effective by the Commission on March 30, 2026 (the “Registration Statement”).

A copy of the legal opinion as to the legality

of the common shares issuable under the Sales Agreement and covered by the prospectus supplement and related prospectus is filed as Exhibit

5.1 attached hereto and is incorporated by reference herein and into the Registration Statement.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits.

Exhibit No.

Description

5.1

Opinion of Norton Rose Fulbright Canada LLP regarding legality of securities being registered

23.1

Consent of Norton Rose Fulbright Canada LLP (contained in Exhibit 5.1)

104

Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

SIGNATURES

Pursuant to the requirements of the Securities

Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INMED PHARMACEUTICALS INC.

Date: April 3, 2026

By:

/s/ Eric A Adams

Eric A Adams

President & CEO

EX-5.1 — OPINION OF NORTON ROSE FULBRIGHT CANADA LLP REGARDING LEGALITY OF SECURITIES BEING REGISTERED

EX-5.1

Filename: ea028498901ex5-1.htm · Sequence: 2

Exhibit 5.1

April 3, 2026

InMed Pharmaceuticals Inc.

815 W. Hastings Street

Vancouver, British Columbia, Canada

V6C 3E8

Norton Rose Fulbright Canada llp

222 Bay Street, Suite 3000, P.O. Box 53

Toronto, Ontario M5K 1E7 Canada

F: +1 416.216.3930

nortonrosefulbright.com

Re: Registration Statement of InMed Pharmaceuticals

Inc. on Form S-3

Dear Sirs/Mesdames:

We have acted as counsel to InMed Pharmaceuticals

Inc. (the Company), in connection with the issuance and sale through H.C. Wainwright & Co., LLC (the Sales Agent) as

the sales agent from time to time by the Company of its common shares (the Common Shares), for aggregate sales value of up to $1,213,648,

to be issued pursuant to a registration statement on Form S-3 (Registration No. 333-294503), under the Securities Act of 1933, as amended

(the Securities Act), filed by the Company with the Securities and Exchange Commission (the Commission) on March 20, 2026,

including the base prospectus contained therein (the Registration Statement), as supplemented by the prospectus supplement dated

April 2, 2026 (the April Prospectus Supplement), relating to the offering of the Common Shares and that certain At The Market Issuance

Offering Agreement, dated as of April 7, 2022, as amended by that certain amendment dated June 27, 2024, between the Company and the Sales

Agent (the ATM Agreement).

As counsel, we have made such investigations and

examined the originals, or duplicate, certified, conformed, telecopied or photostatic copies of such corporate records, agreements, documents

and other instruments and have made such other investigations as we have considered necessary or relevant for the purposes of this opinion,

including:

(a)

the Registration Statement;

(b)

the April Prospectus Supplement;

(c)

the ATM Agreement;

(d)

the articles, as amended, and the notice of articles of the Company; and

(e)

a Certificate of Good Standing dated April 2, 2026 issued by the British Columbia Registrar of Companies.

With respect to the accuracy of factual matters

material to this opinion, we have relied upon certificates or comparable documents and representations of public officials and of officers

of the Company and have not performed any independent check or verification of such factual matters.

Norton Rose Fulbright Canada LLP is a limited

liability partnership established in Canada.

Norton Rose Fulbright Canada LLP, Norton Rose Fulbright LLP, Norton

Rose Fulbright Australia and Norton Rose Fulbright US LLP are separate legal entities and all of them are members of Norton Rose Fulbright

Verein, a Swiss verein. Norton Rose Fulbright Verein helps coordinate the activities of the members but does not itself provide legal

services to clients. Details of each entity, with certain regulatory information, are at nortonrosefulbright.com.

In giving this opinion, we have assumed the genuineness

of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity

to authentic original documents of all documents submitted to us as duplicates, certified, conformed, telecopied or photostatic copies

and the authenticity of the originals of such latter documents, and that all facts set forth in the certificates supplied by officers

of the Company are complete, true and accurate as of the date hereof. We have also assumed that the Certificate of Good Standing referred

to above will continue to be accurate as at the date of issuance of any Common Shares sold under the Registration Statement.

The opinion set forth below is limited to the

laws of the Province of British Columbia and the federal laws of Canada applicable therein, in each case in effect on the date hereof.

Our opinion is rendered as of the date hereof, and we assume no obligation to advise you of changes in law or fact (or the effect thereof

on the opinions expressed herein) that hereafter may come to our attention.

The opinion set forth below is subject to the

following exceptions, limitations and qualifications: (i) the effect of bankruptcy, insolvency, reorganization, arrangement, moratorium,

fraudulent conveyance, fraudulent transfer and other similar laws relating to or affecting the rights of creditors; (ii) the effect of

general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair dealing and

the possible unavailability of specific performance, injunctive relief and other equitable remedies), regardless of whether considered

in a proceeding at law or in equity, (iii) the effect of public policy considerations that may limit the rights of the parties to obtain

further remedies, (iv) we express no opinion with respect to the enforceability of provisions relating to choice of law, choice of venue,

jurisdiction or waivers of jury trial, and (v) we express no opinion with respect to the enforceability of any waiver of any usury defense.

Based on the foregoing, and subject to the assumptions,

limitations and qualifications set forth herein, including the assumption that the Registration Statement and any required post-effective

amendment(s) thereto required by applicable laws have become effective under the Securities Act, we are of the opinion that upon delivery

of and payment for such Common Shares in the manner contemplated by the Registration Statement, the Common Shares will be validly issued,

fully paid and non-assessable shares in the share capital of the Company.

We hereby consent to the filing of this opinion

with the Commission as an exhibit to the Registration Statement and to the use of our name therein. In giving such consent, we do not

thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and

Regulations of the Commission promulgated thereunder.

Yours truly,

/s/ Norton Rose Fulbright Canada LLP

GRAPHIC

Filename: ea028498901_ex5-1img1.jpg · Sequence: 3

Binary file (13740 bytes)

Download ea028498901_ex5-1img1.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 8

v3.26.1

Cover

Apr. 03, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Apr. 03, 2026

Entity File Number

001-39685

Entity Registrant Name

INMED PHARMACEUTICALS INC.

Entity Central Index Key

0001728328

Entity Tax Identification Number

98-1428279

Entity Incorporation, State or Country Code

Entity Address, Address Line One

InMed Pharmaceuticals Inc.

Entity Address, Address Line Two

Suite 1445 - 885 W. Georgia Street

Entity Address, City or Town

Vancouver

Entity Address, State or Province

Entity Address, Country

Entity Address, Postal Zip Code

V6C 3E8

City Area Code

604

Local Phone Number

669-7207

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common Shares, no par value

Trading Symbol

INM

Security Exchange Name

NASDAQ

Entity Emerging Growth Company

true

Elected Not To Use the Extended Transition Period

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

ISO 3166-1 alpha-2 country code.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCountry

Namespace Prefix:

dei_

Data Type:

dei:countryCodeItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 7A

-Section B

-Subsection 2

+ Details

Name:

dei_EntityExTransitionPeriod

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration